Atea Pharmaceuticals Future Growth
Future criteria checks 2/6
Atea Pharmaceuticals's earnings are forecast to decline at 4.8% per annum while its annual revenue is expected to grow at 119.2% per year. EPS is expected to grow by 13.1% per annum. Return on equity is forecast to be -65.4% in 3 years.
Key information
-4.8%
Earnings growth rate
13.1%
EPS growth rate
Pharmaceuticals earnings growth | 23.6% |
Revenue growth rate | 119.2% |
Future return on equity | -65.4% |
Analyst coverage | Low |
Last updated | 16 Sep 2024 |
Recent future growth updates
Recent updates
Atea wins FDA Fast Track status for dengue treatment
Sep 26Atea Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story
May 13Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically
Jan 05Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates
Nov 25A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Oct 24A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Oct 24Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir
Oct 20U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs
Jun 17Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
May 15Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
May 13Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%
Apr 08Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business
Mar 06Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares
Jan 30Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 32 | -211 | -192 | -166 | 2 |
12/31/2025 | 8 | -181 | -204 | -178 | 3 |
12/31/2024 | N/A | -192 | -108 | -81 | 2 |
6/30/2024 | N/A | -176 | -121 | -121 | N/A |
3/31/2024 | N/A | -164 | -95 | -95 | N/A |
12/31/2023 | N/A | -136 | -85 | -85 | N/A |
9/30/2023 | N/A | -131 | -85 | -85 | N/A |
6/30/2023 | N/A | -106 | -89 | -89 | N/A |
3/31/2023 | N/A | -109 | -94 | -92 | N/A |
12/31/2022 | N/A | -116 | -123 | -121 | N/A |
9/30/2022 | 192 | 36 | -177 | -175 | N/A |
6/30/2022 | 225 | 16 | -133 | -131 | N/A |
3/31/2022 | 285 | 48 | -129 | -129 | N/A |
12/31/2021 | 351 | 121 | -87 | -87 | N/A |
9/30/2021 | 208 | 25 | 307 | 307 | N/A |
6/30/2021 | 175 | 35 | 275 | 275 | N/A |
3/31/2021 | 115 | 24 | 284 | 284 | N/A |
12/31/2020 | 49 | -11 | 297 | 297 | N/A |
9/30/2020 | N/A | -36 | -26 | -26 | N/A |
6/30/2020 | N/A | -22 | -20 | -20 | N/A |
3/31/2020 | N/A | -16 | -14 | -14 | N/A |
12/31/2019 | N/A | -14 | -13 | -13 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVIR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AVIR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AVIR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AVIR's revenue (119.2% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: AVIR's revenue (119.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AVIR is forecast to be unprofitable in 3 years.